Spots Global Cancer Trial Database for epirubicin hydrochloride
Every month we try and update this database with for epirubicin hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer | NCT00002866 | Breast Cancer Neutropenia | filgrastim docetaxel epirubicin hydr... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery | NCT00301925 | Breast Cancer | pegfilgrastim capecitabine cyclophosphamid... epirubicin hydr... fluorouracil methotrexate adjuvant therap... | 18 Years - 120 Years | Institute of Cancer Research, United Kingdom | |
| Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer | NCT00004873 | Gastric Cancer | cisplatin docetaxel epirubicin hydr... fluorouracil | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | NCT00309920 | Breast Cancer | darbepoetin alf... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer | NCT00004237 | Breast Cancer | cyclophosphamid... doxorubicin hyd... epirubicin hydr... mitoxantrone hy... vinorelbine tar... conventional su... radiation thera... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma | NCT00822848 | Sarcoma | epirubicin hydr... ifosfamide sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... adjuvant therap... neoadjuvant the... therapeutic con... hypofractionate... | 15 Years - 120 Years | OHSU Knight Cancer Institute | |
| Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer | NCT00020748 | Unspecified Adu... | epirubicin hydr... irinotecan hydr... | 18 Years - | Georgetown University | |
| Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | NCT00066443 | Breast Cancer | pegfilgrastim docetaxel epirubicin hydr... | 16 Years - | Canadian Cancer Trials Group | |
| Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00398489 | Breast Cancer | trastuzumab anastrozole cyclophosphamid... docetaxel epirubicin hydr... goserelin aceta... tamoxifen citra... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients | NCT00820547 | Breast Cancer | bevacizumab cyclophosphamid... docetaxel epirubicin hydr... fluorouracil | 18 Years - | UNICANCER | |
| Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer | NCT00966706 | Pancreatic Canc... | capecitabine cisplatin docetaxel epirubicin hydr... gemcitabine hyd... | 18 Years - 75 Years | IRCCS San Raffaele | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00062296 | Leukemia Lymphoma | rituximab epirubicin hydr... | 18 Years - | Fox Chase Cancer Center | |
| Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients | NCT04418154 | Triple Negative... | epirubicin hydr... Cyclophosphamid... Albumin bound p... Toripalimab | 18 Years - 70 Years | Fudan University | |
| Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | NCT00601705 | Esophageal Canc... Gastric Cancer | cisplatin epirubicin hydr... fluorouracil oxaliplatin adjuvant therap... neoadjuvant the... | 18 Years - | Case Comprehensive Cancer Center | |
| Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery | NCT00301925 | Breast Cancer | pegfilgrastim capecitabine cyclophosphamid... epirubicin hydr... fluorouracil methotrexate adjuvant therap... | 18 Years - 120 Years | Institute of Cancer Research, United Kingdom | |
| Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer | NCT00872625 | Breast Cancer | cyclophosphamid... docetaxel epirubicin hydr... fluorouracil neoadjuvant the... therapeutic con... hypofractionate... image-guided ra... radiation thera... stereotactic ra... | 18 Years - | Centre Antoine Lacassagne | |
| Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer | NCT00645866 | Breast Cancer | capecitabine docetaxel epirubicin hydr... laboratory biom... pharmacogenomic... biopsy neoadjuvant the... therapeutic sur... | 18 Years - | Mayo Clinic | |
| Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | NCT00309920 | Breast Cancer | darbepoetin alf... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer | NCT00379015 | Breast Cancer | trastuzumab cyclophosphamid... docetaxel epirubicin hydr... conventional su... neoadjuvant the... | 20 Years - 65 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | NCT00486356 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Liver Cancer Unspecified Adu... | capecitabine carboplatin epirubicin hydr... microarray anal... polymorphism an... pharmacological... | 18 Years - 120 Years | University of Nebraska | |
| Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors | NCT00878904 | Unspecified Adu... | epirubicin hydr... panobinostat gene expression... protein express... western blottin... immunologic tec... laboratory biom... pharmacological... | 18 Years - 120 Years | University of California, San Francisco | |
| Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | NCT00096304 | Prostate Cancer | docetaxel epirubicin hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Combination Chemotherapy in Treating Women With Breast Cancer | NCT00047099 | Breast Cancer | cyclophosphamid... docetaxel epirubicin hydr... fluorouracil goserelin aceta... tamoxifen citra... adjuvant therap... radiation thera... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | NCT00053911 | Breast Cancer | anastrozole cyclophosphamid... docetaxel epirubicin hydr... fluorouracil goserelin aceta... tamoxifen citra... adjuvant therap... | 18 Years - 65 Years | UNICANCER | |
| Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | NCT00311636 | Breast Cancer | cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil methotrexate paclitaxel triptorelin adjuvant therap... | 18 Years - 45 Years | National Cancer Institute (NCI) | |
| Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery | NCT00963729 | Breast Cancer | cyclophosphamid... docetaxel epirubicin hydr... fluorouracil letrozole | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer | NCT00966706 | Pancreatic Canc... | capecitabine cisplatin docetaxel epirubicin hydr... gemcitabine hyd... | 18 Years - 75 Years | IRCCS San Raffaele | |
| Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer | NCT00070278 | Breast Cancer | cyclophosphamid... epirubicin hydr... gemcitabine hyd... paclitaxel comparative gen... microarray anal... mutation analys... conventional su... neoadjuvant the... | - | National Cancer Institute (NCI) | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | NCT00433420 | Breast Cancer | pegfilgrastim cyclophosphamid... epirubicin hydr... fluorouracil paclitaxel adjuvant therap... | 18 Years - 70 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer | NCT00005583 | Endometrial Can... | cisplatin doxorubicin hyd... epirubicin hydr... adjuvant therap... conventional su... radiation thera... | - | National Cancer Institute (NCI) | |
| Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | NCT00096304 | Prostate Cancer | docetaxel epirubicin hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | NCT00096304 | Prostate Cancer | docetaxel epirubicin hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | NCT00601705 | Esophageal Canc... Gastric Cancer | cisplatin epirubicin hydr... fluorouracil oxaliplatin adjuvant therap... neoadjuvant the... | 18 Years - | Case Comprehensive Cancer Center | |
| Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | NCT01123473 | Adenocarcinoma ... Gastric Cancer | capecitabine cisplatin epirubicin hydr... fluorouracil lapatinib ditos... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer | NCT00004873 | Gastric Cancer | cisplatin docetaxel epirubicin hydr... fluorouracil | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery | NCT00963729 | Breast Cancer | cyclophosphamid... docetaxel epirubicin hydr... fluorouracil letrozole | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer | NCT01880385 | Inflammatory Br... | Bevacizumab Cyclophosphamid... epirubicin hydr... fluorouracil Docetaxel Trastuzumab | 20 Years - 75 Years | Association Tunisienne de lutte Contre le Cancer | |
| Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | NCT00433420 | Breast Cancer | pegfilgrastim cyclophosphamid... epirubicin hydr... fluorouracil paclitaxel adjuvant therap... | 18 Years - 70 Years | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer | NCT00629278 | Breast Cancer | trastuzumab aromatase inhib... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel releasing hormo... tamoxifen citra... adjuvant therap... radiation thera... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00398489 | Breast Cancer | trastuzumab anastrozole cyclophosphamid... docetaxel epirubicin hydr... goserelin aceta... tamoxifen citra... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | NCT00014222 | Breast Cancer | epoetin alfa filgrastim cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil paclitaxel | - 60 Years | Canadian Cancer Trials Group | |
| High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer | NCT00002870 | Breast Cancer | filgrastim cyclophosphamid... epirubicin hydr... fluorouracil thiotepa peripheral bloo... | 18 Years - 59 Years | UNICANCER | |
| High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer | NCT00002870 | Breast Cancer | filgrastim cyclophosphamid... epirubicin hydr... fluorouracil thiotepa peripheral bloo... | 18 Years - 59 Years | UNICANCER | |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | NCT02315196 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | pegylated lipos... epirubicin hydr... carboplatin therapeutic con... paclitaxel laboratory biom... quality-of-life... | 18 Years - | Rutgers, The State University of New Jersey | |
| Tamoxifen in Treating Women With High-Risk Breast Cancer | NCT00002542 | Breast Cancer | CMF regimen cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil methotrexate tamoxifen citra... radiation thera... | - 120 Years | Canadian Cancer Trials Group | |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | NCT02315196 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | pegylated lipos... epirubicin hydr... carboplatin therapeutic con... paclitaxel laboratory biom... quality-of-life... | 18 Years - | Rutgers, The State University of New Jersey | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients | NCT04736394 | Non-muscle Inva... | APL-1202 Epirubicin Hydr... | 18 Years - | Jiangsu Yahong Meditech Co., Ltd aka Asieris | |
| Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery | NCT00311636 | Breast Cancer | cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil methotrexate paclitaxel triptorelin adjuvant therap... | 18 Years - 45 Years | National Cancer Institute (NCI) | |
| Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma | NCT00755976 | Melanoma (Skin) | epirubicin hydr... sulindac immunologic tec... | 18 Years - | Cancer Trials Ireland | |
| Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer | NCT00002529 | Breast Cancer | cyclophosphamid... doxorubicin hyd... epirubicin hydr... tamoxifen citra... toremifene | - 70 Years | ETOP IBCSG Partners Foundation | |
| Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer | NCT00052910 | Esophageal Canc... Gastric Cancer | cisplatin epirubicin hydr... fluorouracil leucovorin calc... radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | NCT00003852 | Childhood Germ ... Extragonadal Ge... Ovarian Cancer Testicular Germ... | filgrastim carboplatin cyclophosphamid... epirubicin hydr... etoposide ifosfamide paclitaxel thiotepa bone marrow abl... peripheral bloo... | 15 Years - 120 Years | UNICANCER | |
| Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 | NCT00753207 | Breast Cancer | epirubicin hydr... lapatinib ditos... biomarker analy... immunohistochem... liquid chromato... mass spectromet... | 18 Years - 120 Years | Cancer Trials Ireland | |
| Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | NCT00005581 | Breast Cancer | cyclophosphamid... epirubicin hydr... fluorouracil paclitaxel | - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer | NCT00003577 | Breast Cancer | CMF regimen cyclophosphamid... epirubicin hydr... fluorouracil methotrexate adjuvant therap... radiation thera... | - | National Cancer Institute (NCI) | |
| Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | NCT00253500 | Breast Cancer | pegfilgrastim epirubicin hydr... conventional su... | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer | NCT00010140 | Breast Cancer | docetaxel epirubicin hydr... tamoxifen citra... adjuvant therap... | - | National Cancer Institute (NCI) | |
| Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer | NCT00872625 | Breast Cancer | cyclophosphamid... docetaxel epirubicin hydr... fluorouracil neoadjuvant the... therapeutic con... hypofractionate... image-guided ra... radiation thera... stereotactic ra... | 18 Years - | Centre Antoine Lacassagne | |
| Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor | NCT00021047 | Esophageal Canc... Extrahepatic Bi... Gastric Cancer Head and Neck C... Liver Cancer Unspecified Adu... | capecitabine carboplatin epirubicin hydr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin | NCT00022178 | Carcinoma of Un... | cisplatin cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil vincristine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer | NCT00008034 | Breast Cancer | capecitabine cyclophosphamid... epirubicin hydr... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer | NCT00011921 | Lung Cancer | filgrastim carboplatin epirubicin hydr... etoposide etoposide phosp... ifosfamide paclitaxel autologous bone... bone marrow abl... peripheral bloo... radiation thera... | - 65 Years | National Cancer Institute (NCI) | |
| Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer | NCT00002615 | Gastric Cancer | cisplatin epirubicin hydr... fluorouracil conventional su... | - | National Cancer Institute (NCI) | |
| Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009) | NCT01031030 | Breast Cancer | cyclophosphamid... epirubicin hydr... fluorouracil methotrexate laboratory biom... adjuvant therap... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer | NCT00010140 | Breast Cancer | docetaxel epirubicin hydr... tamoxifen citra... adjuvant therap... | - | National Cancer Institute (NCI) | |
| Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer | NCT00003893 | Breast Cancer | CMF regimen cyclophosphamid... doxorubicin hyd... epirubicin hydr... fluorouracil methotrexate mitomycin C mitoxantrone hy... adjuvant therap... radiation thera... | - | National Cancer Institute (NCI) | |
| Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | NCT00066443 | Breast Cancer | pegfilgrastim docetaxel epirubicin hydr... | 16 Years - | Canadian Cancer Trials Group | |
| Combination Chemotherapy in Treating Patients With Esophageal Cancer | NCT00041262 | Esophageal Canc... | cisplatin epirubicin hydr... fluorouracil conventional su... neoadjuvant the... | - | National Cancer Institute (NCI) | |
| MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer | NCT00462696 | Breast Cancer | docetaxel epirubicin hydr... conventional su... dynamic contras... neoadjuvant the... radiomammograph... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT00003606 | Lung Cancer | cisplatin cyclophosphamid... epirubicin hydr... etoposide radiation thera... | 18 Years - 75 Years | UNICANCER | |
| Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer | NCT00002529 | Breast Cancer | cyclophosphamid... doxorubicin hyd... epirubicin hydr... tamoxifen citra... toremifene | - 70 Years | ETOP IBCSG Partners Foundation | |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer | NCT01094964 | Bladder Cancer | BCG solution recombinant int... epirubicin hydr... mitomycin C laboratory biom... hyperthermia tr... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | NCT00005584 | Lymphoma | bleomycin sulfa... ABVD regimen BEACOPP regimen epirubicin hydr... prednisone vinblastine sul... radiation thera... | 15 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | NCT00005581 | Breast Cancer | cyclophosphamid... epirubicin hydr... fluorouracil paclitaxel | - 70 Years | National Cancer Institute (NCI) | |
| Epirubicin and Thalidomide in Treating Patients With Liver Cancer | NCT00058487 | Liver Cancer | epirubicin hydr... thalidomide | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
